The outlook of companies tied to flagship drugs like Viagra presents a challenging investment landscape . While the initial boom of copyright, fueled by Viagra's remarkable popularity, generated substantial returns, the expiry in key regions has introduced significant risk . Investors are now grappling with the effect of rival medications , diminis